Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Pathologica ; 113(4): 285-293, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34463673

ABSTRACT

Multiple myeloma accounts for 10-15% of all hematologic malignancies, and 20% of deaths related to cancers of the blood and bone marrow. Diagnosis is defined by the presence of a serum monoclonal spike (M-spike) of more than 3 g/dL or more than 10% clonal plasma cells in the bone marrow and at least one myeloma-defining event, such as hypercalcemia, anemia, bone lesions, or renal impairment. The kidney is a major target organ, and renal impairment is frequently the first manifestation of the disease. Renal damage occurs in up to 40% of patients and 10-20% will require dialysis. Monoclonal immunoglobulin light chains are the major causes of renal complications in multiple myeloma. Glomerular disease, with the deposition of monoclonal immunoglobulins or their components, includes monoclonal immunoglobulin deposition disease, AL or AH amyloidosis, type I cryoglobulinemia, proliferative glomerulonephritis with monoclonal IgG deposits, immunotactoid glomerulopathy, and fibrillary glomerulonephritis. In addition, tubulointerstitial diseases with the deposition of monoclonal immunoglobulins or their components, are constituted by light chain cast nephropathy, light chain proximal tubulopathy, and crystal-storing histiocytosis.We report the case of a 66-year-old woman who presented with albumin-predominant moderate proteinuria and renal failure. Serum and urine immunofixation electrophoresis showed monoclonal κ light chain in both. Renal biopsy confirmed κ-restricted crystal-storing renal disease involving proximal tubular epithelial cells and crystal storing histiocytosis. Multiple myeloma with crystal storing histiocytosis was discovered in bone marrow biopsy. Thus, we present an unusual case of a myeloma patient presenting light chain proximal tubulopathy and crystal-storing histiocytosis both in the kidney and in the bone marrow.


Subject(s)
Histiocytosis , Kidney Diseases , Multiple Myeloma , Paraproteinemias , Aged , Female , Histiocytosis/complications , Humans , Kidney , Multiple Myeloma/complications , Paraproteinemias/complications
2.
G Ital Nefrol ; 38(1)2021 Feb 16.
Article in Italian | MEDLINE | ID: mdl-33599424

ABSTRACT

Waldenström's disease is a rare haematological neoplasm involving B lymphocytes, characterized by medullary infiltrated lymphoplasmacytic lymphoma and by the presence of a monoclonal M paraprotein. Although rarely, this condition may lead to heterogeneous renal involvement and cause severe renal failure. We report the clinical case of a patient with overt nephrotic syndrome in Waldenström's disease treated with a combination chemotherapy (rituximab, cyclophosphamide, dexamethasone) until complete renal and haematological remission.


Subject(s)
Nephrotic Syndrome , Waldenstrom Macroglobulinemia , Cyclophosphamide , Humans , Kidney , Nephrotic Syndrome/drug therapy , Nephrotic Syndrome/etiology , Rituximab , Waldenstrom Macroglobulinemia/complications , Waldenstrom Macroglobulinemia/drug therapy
3.
Intern Emerg Med ; 15(8): 1409-1414, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32930963

ABSTRACT

The epidemic phase of Coronavirus disease 2019 (COVID-19) made the Worldwide health system struggle against a severe interstitial pneumonia requiring high-intensity care settings for respiratory failure. A rationalisation of resources and a specific treatment path were necessary. The study suggests a predictive model drawing on clinical data gathered by 119 consecutive patients with laboratory-confirmed COVID-19 admitted in Busto Arsizio hospital. We derived a score that identifies the risk of clinical evolution and in-hospital mortality clustering patients into four groups. The study outcomes have been compared across the derivation and validation samples. The prediction rule is based on eight simple patient characteristics that were independently associated with study outcomes. It is able to stratify COVID-19 patients into four severity classes, with in-hospital mortality rates of 0% in group 1, 6-12.5% in group 2, 7-20% in group 3 and 60-86% in group 4 across the derivation and validation sample. The prediction model derived in this study identifies COVID-19 patients with low risk of in-hospital mortality and ICU admission. The prediction model that the study presents identifies COVID-19 patients with low risk of in-hospital mortality and admission to ICU. Moreover, it establishes an intermediate portion of patients that should be treated accurately in order to avoid an unfavourable clinical evolution. A further validation of the model is important before its implementation as a decision-making tool to guide the initial management of patients.


Subject(s)
Clinical Decision Rules , Coronavirus Infections/diagnosis , Pneumonia, Viral/diagnosis , Risk Assessment/standards , Adult , Aged , Aged, 80 and over , COVID-19 , Coronavirus Infections/physiopathology , Female , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/physiopathology , Reproducibility of Results , Risk Assessment/methods , Risk Assessment/statistics & numerical data , Severity of Illness Index
4.
Ann Ital Med Int ; 18(1): 51-5, 2003.
Article in Italian | MEDLINE | ID: mdl-12739430

ABSTRACT

The present case report refers to a multiorgan autoimmune disease manifesting following thymectomy performed for a benign thymoma. This disease is characterized by hypothyroidism, severe myasthenia, polymyositis and alopecia which are organ-specific diseases probably with a different time of onset but which are all an expression of the same immunopathologic process occurring in individuals who have a genetic predisposition. Characteristic of the present case is not only the association of the different immunopathologic clinical pictures but also the rather difficult differential diagnosis between a hypothyroidism-related myopathy and polymyositis. It was possible to formulate the diagnosis by integrating the results of clinical and laboratory evaluation with the therapeutic outcome. The onset of the syndrome was attributed to the withdrawal, following surgery, of the inhibitory effects of the thymoma on some clones of autoreactive lymphocytes.


Subject(s)
Autoimmune Diseases/blood , Autoimmune Diseases/diagnosis , Alopecia/blood , Alopecia/diagnosis , Autoimmune Diseases/enzymology , Autoimmune Diseases/immunology , Creatine Kinase/blood , Female , HLA-DR3 Antigen/blood , Humans , Hypothyroidism/blood , Hypothyroidism/diagnosis , Middle Aged , Myasthenia Gravis/blood , Myasthenia Gravis/diagnosis , Polymyositis/blood , Polymyositis/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...